- Home
- ZENA vs SEPN Comparison
ZENA vs SEPN Comparison
Compare ZENA & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENA
- SEPN
- Stock Information
- Founded
- ZENA 2017
- SEPN 2022
- Country
- ZENA Canada
- SEPN United States
- Employees
- ZENA N/A
- SEPN N/A
- Industry
- ZENA
- SEPN
- Sector
- ZENA
- SEPN
- Exchange
- ZENA NYSE
- SEPN NYSE
- Market Cap
- ZENA 109.4M
- SEPN 453.2M
- IPO Year
- ZENA N/A
- SEPN 2024
- Fundamental
- Price
- ZENA $3.59
- SEPN $10.49
- Analyst Decision
- ZENA Strong Buy
- SEPN Strong Buy
- Analyst Count
- ZENA 1
- SEPN 5
- Target Price
- ZENA $9.00
- SEPN $26.75
- AVG Volume (30 Days)
- ZENA 10.0M
- SEPN 541.8K
- Earning Date
- ZENA 01-01-0001
- SEPN 08-15-2025
- Dividend Yield
- ZENA N/A
- SEPN N/A
- EPS Growth
- ZENA N/A
- SEPN N/A
- EPS
- ZENA N/A
- SEPN N/A
- Revenue
- ZENA $1,744,794.00
- SEPN $977,000.00
- Revenue This Year
- ZENA N/A
- SEPN N/A
- Revenue Next Year
- ZENA N/A
- SEPN $526.96
- P/E Ratio
- ZENA N/A
- SEPN N/A
- Revenue Growth
- ZENA 24.50
- SEPN 108.76
- 52 Week Low
- ZENA $1.41
- SEPN $4.17
- 52 Week High
- ZENA $12.43
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- ZENA N/A
- SEPN N/A
- Support Level
- ZENA N/A
- SEPN N/A
- Resistance Level
- ZENA N/A
- SEPN N/A
- Average True Range (ATR)
- ZENA 0.00
- SEPN 0.00
- MACD
- ZENA 0.00
- SEPN 0.00
- Stochastic Oscillator
- ZENA 0.00
- SEPN 0.00
About ZENA ZENATECH INC
ZenaTech Inc is a enterprise software technology company that specializes in mission-critical cloud-based applications integrated with smart hardware to deliver solutions across diverse industries. The company operates in software development technology, sales, and distribution. The company is also developing a drone manufacturing, sales, and distribution business. It generates revenue from software licensing and subscription agreements, software support and maintenance, and technology consulting services.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.